Reported 2 days ago
Eli Lilly's stock soared by over 14% after announcing positive results from its Phase 3 trial of orforglipron, a new oral GLP-1 weight loss medication, which showed significant efficacy and a favorable safety profile. This news negatively impacted competitors Novo Nordisk and Viking Therapeutics, whose stocks declined as Lilly's proven clinical data positions it favorably in the weight loss market, potentially giving it a competitive edge without the need for injections.
Source: YAHOO